PFE Mar 2025 20.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 12:58PM EDT. Market open.
| Previous Close | 0.2600 |
| Open | 0.2800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 20.00 |
| Expire Date | 2025-03-21 |
| Day's Range | 0.2600 - 0.2800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Business WireELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
NEW YORK, June 14, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
Investor's Business DailySarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.
Barrons.comPfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
The drug company said a gene therapy it is testing failed to improve motor function in boys aged 4 to 7.
© 2024 Yahoo. All rights reserved.